Lessons from a failed γ-secretase Alzheimer trial.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25417150.
- Also identified by DOI 10.1016/j.cell.2014.10.016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
γ-Secretase proteases have been associated with pathology in Alzheimer disease (AD), but we are just beginning to understand their basic mechanisms and physiological roles. A negative drug trial with a broad spectrum γ-secretase inhibitor in AD patients has severely dampened enthusiasm for the potential of pursuing γ-secretase research therapeutically. This pessimism is unwarranted: analysis of available information presented here demonstrates significant confounds for interpreting the outcome of the trial and argues that the major lessons pertain to broad knowledge gaps that are imperative to fill.
Medical subject headings
- Alanine
- Alzheimer Disease
- Amyloid Precursor Protein Secretases
- Azepines
- Clinical Trials as Topic